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A cute promyelocytic leukemia (APL) is a biologi-cally and clinically distinct variant of acute 
myeloid leukemia.  APL is currently classified as acute 
promyelocytic leukemia with t(15 ; 17)(q24.1 ; q21.2);  
PML-RARA in the World Health Organization classifi-
cation system [1].  APL presents a hematological emer-
gency with a high rate of critical hemorrhage due to 
characteristic coagulopathy,  and a patient with APL 
needs urgent intervention by differentiation-inducing 
therapy.  APL has become a highly curable disease due 
to the introduction of differentiation-inducing therapy 
[2].  However,  if a patient with APL has another solid 
organ tumor at the same time,  treatment for the tumor 
should also be done properly.  Synchronous multiple 
primary malignant tumor (sMPMT) is a condition in 
which more than one type of cancer is diagnosed in the 
same individual within 2 months [3].
A single-center study that analyzed hematological 
malignancy patients with sMPMT demonstrated that 
the presence of sMPMT was not a significant prognostic 
factor [4],  suggesting that it will be important to appro-
priately treat both the hematological malignancy and 
the concomitant solid tumor.  Differentiation-inducing 
therapy by all-trans retinoic acid (ATRA) is the main 
initial therapy for untreated APL,  and arsenic trioxide 
(ATO) is used to treat refractory or relapsed APL as a 
more potent differentiation-inducing agent.  The effi-
cacy of ATRA+ATO therapy without cytotoxic chemo-
therapy has been reported as an initial treatment for 
untreated APL [5 , 6].  In these reports,  cytotoxic che-
motherapy was omitted through all phases of the initial 
treatment of untreated APL including induction,  con-
solidation,  and maintenance,  and the event-free sur-
vival and overall survival rates were not inferior to those 
achieved with ATRA+cytotoxic chemotherapy.  In addi-
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tion,  the hematological toxicity and the risk of infec-
tions were significantly reduced in the ATRA+ATO 
therapy group.
Considering these reports,  it appears that consoli-
dation therapy using ATO instead of cytotoxic chemo-
therapy might be preferable for patients with both 
untreated APL and solid organ tumor complications 
because of its lesser hematological toxicity.  In addition,  
there are several reports regarding the treatment of sec-
ondary APL after chemotherapy for a solid organ tumor 
[7 , 8],  but to the best of our knowledge,  there are no 
reports about the treatment of untreated APL together 
with a solid organ tumor.  Here,  we report the first case 
of untreated APL and synchronous endometrial cancer 
treated successfully with ATO consolidation therapy 
instead of cytotoxic chemotherapy.  The patient then 
underwent surgery and weekly TC therapy: paclitaxel 
(PTX) plus carboplatin (CBDCA) for the treatment of 
endometrial cancer.
Case Description
A 67-year-old Japanese female (one normal vaginal 
delivery,  menopause at 48 years old,  body surface area 
1.636 m2 with abnormal uterine bleeding) was diag-
nosed with endometrial cancer,  stage IIIc (T2N1M0).  
The pathological phenotype was serous adenocarci-
noma.  The patient simultaneously had pancytopenia 
and bleeding tendency.  Bone marrow aspiration (BMA) 
revealed atypical promyelocytes with Auer rods which 
comprised 86% of nucleated cells.  The G-banding 
karyotype was t(15 ; 17) (q22 ; q21),  and fluorescence 
in situ hybridization showed PML/RARA fusion signal.  
The patient was diagnosed as having APL.  Her white 
blood cell (WBC) and platelet counts were 410/μl and 
3,100/μl,  respectively and the risk of stratification,  as 
defined by the PHETHEMA and GIMEMA cooperative 
groups,  was intermediate [9].  The laboratory data,  
tumor marker and BMA findings are shown in Table 1.  
Images of the atypical promyelocytes in a BMA smear 
and the endometrial cancer shown by an enhanced 
computed tomography (CT) scan are provided in Fig. 1.
Because of its poor prognosis,  the patient’s APL was 
treated prior to her endometrial cancer.  First,  the 
patient received ATRA (45 mg/m2 daily) as induction 
therapy,  and the WBC count gradually increased.  
Idarubicin (IDR,  8 mg/m2 daily,  3 days) and cytarabine 
(Ara-C,  100 mg/m2 daily,  5 days) were added from day 
13.  After this cytotoxic chemotherapy,  APL cells were 
not detected in peripheral blood,  but the number of 
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Table 1　
CBC Biochemistry and tumor marker BMA
WBC 410 /μL TP 6.7 g/dL NCC 85,000 /μL
　Neu 12 % Alb 4.3 g/dL APL cell 86 %
　Lymph 82.5 % T.Bil 0.6 mg/dL G-banding
　Atypical Lymph 1 % AST 17 U/L 46XX, t(15 ; 17)(q22 ; q12)
　APL cell 4.5 % ALT 16 U/L ［19/20］
RBC 280×106 /μL γ-GTP 16 U/L FISH
Hb 9.8 g/dL Cre 0.52 mg/dL PML/RARA fusion signal 99/100
Plt 3,100 /μL BUN 14 mg/dL
Na 141 mmol/L
Coagulation test K 4 mmol/L
PT 11.7 sec Cl 108 mmol/L
APTT 28.9 sec CEA 1.3 ng/mL
Fib 170 mg/dL CA19-9 9.4 U/mL
ATⅢ 99 % CA125 56 U/mL
FDP 47.5 μg/mL
D-dimer 18.6 μg/mL
CBC,  complete blood count; RBC,  red blood cell; WBC,  white blood cell; Neu,  neutrophil; Lymph,  lymphocyte; APL,  acute promyelo-
cytic leukemia; Hb,  hemoglobin; Plt,  platelet; PT,  prothrombin time; APTT,  activated partial thromboplastin time; Fib,  fibrinogen; FDP,  
fibrin degradation product; TP,  total protein; Alb,  albumin; T. Bil,  total bilirubin; AST,  aspartate aminotransferase; ALT,  alanine amino-
transferase; γ-GTP,  γ-glutamyl transpeptidase; Cre,  creatinine; BUN,  blood urea nitrogen; CEA,  carcinoembryonic antigen; CA-19-9,  
carbohydrate antigen 19-9; CA125,  carbohydrate antigen 125; BMA,  bone marrow aspiration; NCC,  nucleated cell count; FISH,  fluores-
cence in situ hybridization.
WBCs decreased.  Pancytopenia recovery was on day 47 
(from the induction of therapy),  and the patient 
achieved complete cytogenetic remission on day 51 
(Fig. 2).
After the induction therapy,  ATO (0.15 mg/kg daily,  
on weekdays) was given as consolidation therapy instead 
of chemotherapy,  and complete molecular remission 
was confirmed.  Due to mild hematological toxicity,  
surgery for endometrial cancer (abdominal simple hys-
terectomy,  bilateral appendectomy,  pelvic and 
para-aortic lymph node dissection,  and omentectomy) 
was conducted 10 days after the ATO administration.  
The bleeding volume was 510 g.  Following the success-
ful surgery,  a second cycle of ATO (0.15 mg/kg daily,  
on weekdays) was safely added.  Complete molecular 
remission was obtained after the 2 courses of consolida-
tion therapy (Fig. 3).
A CT scan of the patient’s chest after consolidation 
therapy for APL at 142 days after her first admission 
revealed a single 8-mm-dia.  lung metastasis of endo-
metrial cancer.  The patient had been treated with 18 
cycles of weekly TC therapy: PTX (80 mg/m2) and 
CBDCA (area under the blood concentration-time 
curve = 2) [10] instead of maintenance therapy with 
APL,  resulting in a complete response to the lung 
metastasis (Fig. 4).  Three months after the chemother-
apy,  endometrial cancer remained undetected,  and 
APL had been under complete molecular remission.
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Fig. 1　 Bone marrow aspiration smear image and contrast CT scan.  A,  BMA smear at the patientʼs first admission day (May-Giemsa 
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Fig. 2　 Induction therapy for APL.  The 
patient first received all-trans-retinoic acid 
(ATRA) only as induction therapy,  but the 
number of leukocytes gradually increased.  
Cytotoxic chemotherapy was introduced from 
day 13,  and a cytogenetic CR was achieved 
on day 51.  APL,  acute promyelocytic leuke-
mia; APL,  acute promyelocytic leukemia;  
AraC,  cytarabine; ATRA,  all trans-retinoic 
acid; CR,  complete remission; CRc,  complete 
cytogenetic remission; IDR,  idarubicin; Neu,  
neutrophil; WBC,  white blood cell.
The patient then started to receive tamibarotene 
(Am80,  6 mg/m2 daily) as maintenance therapy for 
APL.  Six months after the start of the Am80 mainte-
nance therapy,  the reappearance of lung metastasis and 
the enlargement of the para-aortic lymph node were 
confirmed by CT scans.  The patient was diagnosed with 
recurrent endometrial cancer and was administered 15 
additional cycles of weekly TC therapy.  A complete 
response was achieved again and maintained for 6 
months with no recurrence of APL for 3 years.












Weekly TC therapy 18 cycle (PTX 80mg/m2/day, CBDCA AUC=2)
day142 day383








55 65 75 85 95 105 115 125 135 145 155
WBC (/µl)
Neu (/µl)
ATO 2 cycle 
0.15mg/kg/day on
weekdays
Days after first admission
CRm




Fig. 3　 Consolidation therapy for APL 
and surgery for endometrial cancer.  ATO 
was given as consolidation therapy,  and a 
CR was confirmed at the molecular level.  
Due to the presence of mild hematological 
toxicity,  surgery was conducted for the 
patientʼs endometrial cancer soon after the 
ATO treatment.  Following the successful 
surgery,  a second cycle of ATO was also 
safely administered.  The patient continued 
to show a CR after two courses of the con-
solidation therapy.  ATO,  arsenic trioxide;  
CR,  complete remission; CRm,  complete 
molecular remission; Neu,  neutrophil.
Fig. 4　 Chemotherapy for met-
astatic endometrial cancer.  After 
the second cycle of ATO therapy,  
the chest CT scan showed a sin-
gle metastasis of endometrial 
cancer in the lung (red arrow).  
The patient had been treated with 
18 cycles of weekly PTX and 
CBDCA instead of maintenance 
therapy for APL,  resulting in a 
complete response to lung metas-
tasis.  APL,  acute promyelocytic 
leukemia; ATO,  arsenic trioxide;  
AUC,  area under the blood con-
centration-time curve; CBDCA,  
carboplatin; PTX,  paclitaxel.
Discussion
Prolonged cytopenia following the first course of 
chemotherapy for a hematologic malignancy can be 
challenging for the subsequent treatment of solid organ 
tumors.  A relatively less cytotoxic therapy,  such as 
ATO,  seemed a reasonable option for a subsequent sur-
gery or chemotherapy of a solid organ tumor.  Here,  we 
successfully treated both the patient’s untreated APL and 
her endometrial cancer,  using ATO as consolidation 
therapy for APL; the subsequent surgery and chemo-
therapy for endometrial cancer were conducted suc-
cessfully due to the lesser hematological toxicity of 
ATO.
More recently,  differentiation-inducing therapy 
using ATRA and ATO has been the trend of treatment 
for untreated APL.  Nowadays this is preferred through 
all phases of treatment over the conventional use of 
ATRA combined with chemotherapy,  especially for 
cases with low/intermediate-risk APL.  Lococo et al.  
reported that the efficacy of ATRA+ATO therapy was 
not inferior to that of ATRA+cytotoxic chemotherapy 
for low/intermediate-risk APL,  and the hematological 
toxicity and the risk of infections were increased in the 
patients who received ATRA+cytotoxic chemotherapy 
[5].  Moreover,  Burnett et al.  reported the efficacy and 
safety of the ATO+ATRA approach in multiple risk 
groups [6].  These 2 randomized trials also confirmed 
that ATO+ATRA was hematologically less toxic com-
pared to ATRA-cytotoxic chemotherapy.  Considering 
these 2 reports,  ATO consolidation might be the pre-
ferred choice for the prompt subsequent treatment of 
patients with untreated APL and a solid organ tumor.
In addition,  there is a case report that showed the 
efficacy of ATO in the treatment of platinum-resistant 
recurrent endometrial cancer [11].  However,  because 
cytotoxic chemotherapy has played such an important 
role in as an option for untreated APL for many years,  
careful monitoring for recurrence should be done if 
cytotoxic chemotherapy was omitted.
A single-center study revealed that the presence of 
sMPMT was not a significant risk factor for newly diag-
nosed hematological patients,  and it is important to 
provide adequate treatment for both hematological 
malignancies and solid tumors [4].  In that study,  the 
order of treatment was not associated with the progno-
sis; rather,  it was decided based on the prognosis of the 
combination of diseases and various other factors.  
Untreated APL has had an extremely poor prognosis 
because of the risk of hemorrhagic death,  and differen-
tiation therapy should thus be performed promptly [2].  
On the other hand,  the treatment of our present 
patient’s endometrial cancer was not urgent,  as the 
reported 5-year survival of endometrial stage IIIc can-
cer was 65% [12].  Taken together,  the above-men-
tioned findings led us to initiate the treatment for APL 
prior to that for endometrial cancer in our patient.  
There are few studies about the treatment of patients 
with a hematological malignancy and sMPMT,  and 
further research is necessary to establish the optimal 
treatment.
In our patient’s case,  we conducted TC therapy for 
the recurrence of endometrial cancer.  TC therapy has 
resulted in less peripheral neuropathy,  and the non-in-
feriority of TC therapy to TAP therapy (i.e.,  paclitaxel,  
doxorubicin,  and cisplatin,  which was the standard 
first-line therapy for recurrent endometrial cancer) was 
reported in an interim analysis of the GOG209 trial 
[13].  On the other hand,  for the maintenance therapy 
of our patient’s untreated APL,  we used Am80 because 
the 7-year relapse-free survival rate was significantly 
higher in Am80 maintenance compared to that of 
ATRA in all-risk untreated APL patients [14].
In conclusion,  we experienced a patient with 
untreated APL and synchronous endometrial cancer.  
Her APL was successfully treated with ATO consolida-
tion therapy instead of cytotoxic chemotherapy,  fol-
lowed by surgery and chemotherapy for her endome-
trial cancer.  Consolidation therapy by ATO might be 
preferable in such a case,  because of its lesser hemato-
logical toxicity.
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